EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

5563 reported adverse events

Drug classes: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]

These side effects are most commonly reported by patients taking EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE:

#	Side effect	Count
0	BONE DENSITY DECREASED	3091
1	RENAL INJURY	2565
2	SKELETAL INJURY	2396
3	TOOTH LOSS	1710
4	CHRONIC KIDNEY DISEASE	1660
5	TOOTH INJURY	1651
6	RENAL FAILURE	1325
7	BONE LOSS	1293
8	MULTIPLE FRACTURES	1254
9	OSTEONECROSIS	1252

See all common reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE

EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE is most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	TOOTH INJURY	1651	0.5099
1	SKELETAL INJURY	2396	0.2529
2	BONE DEMINERALISATION	76	0.1704
3	BONE DENSITY DECREASED	3091	0.1170
4	DEGENERATIVE BONE DISEASE	26	0.1102
5	BONE LOSS	1293	0.1051
6	TOOTH LOSS	1710	0.1037
7	RENAL INJURY	2565	0.0947
8	MULTIPLE FRACTURES	1254	0.0934
9	COELIAC ARTERY ANEURYSM	1	0.0714

See all enriched reactions for EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE